Neuroendocrine cells in prostate cancer correlate with poor outcomes: a systematic review and meta‐analysis
- 16 November 2021
- journal article
- review article
- Published by Wiley in BJU International
- Vol. 130 (4) , 420-433
Abstract
Objectives: To perform a systematic review and meta‐analysis of the literature to understand the variation in the reporting of neuroendocrine staining and determine the influence of reporting neuroendocrine staining at diagnosis on patient outcomes. Methods: Medical databases were searched to identify studies in which adenocarcinoma specimens were stained with any of the following four neuroendocrine markers: chromogranin A (CgA), neuron‐specific enolase (NSE), synaptophysin and CD56. The prevalence of neuroendocrine staining and correlation of the prevalence of neuroendocrine staining to patient outcomes were analysed using a random‐effects model. All statistical tests were two‐sided. Results: Sixty‐two studies spanning 7616 patients were analysed. The pooled prevalence for the most common marker, CgA (41%), was similar to that of NSE (39%) and higher than that of synaptophysin (31%). The prevalence of CgA staining was significantly influenced by reporting criteria, where objective thresholds reduced the variation in prevalence to 26%. No correlation was found between CgA prevalence and tumour grade. Patients positive for CgA staining using objective criteria had more rapid biochemical progression (hazard ratio [HR] 1.98, 95% confidence interval [CI] 1.49 to 2.65) and poorer prostate cancer‐specific survival (HR 7.03, 95% CI 2.55 to 19.39) compared to negative patients, even among those with low‐risk cancers. Conclusion: Discrepancies in the reported prevalence of neuroendocrine cells in adenocarcinoma are driven by the inconsistent scoring criteria. This study unequivocally demonstrates that when neuroendocrine cell staining is assessed with objective criteria it identifies patients with poor clinical outcomes. Future studies are needed to determine the exact quantifiable thresholds for use in reporting neuroendocrine cell staining to identify patients at higher risk of progression.Keywords
Funding Information
- National Health and Medical Research Council (1102752, 1090204, 1185616)
- Prostate Cancer Foundation of Australia (YI 0417)
This publication has 78 references indexed in Scilit:
- Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancerVirchows Archiv, 2012
- The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen‐deprivation therapyThe Prostate, 2010
- Prognostic significance of focal neuroendocrine differentiation in prostate cancer: Cases with autopsy-verified cause of deathIndian Journal of Urology, 2010
- Immunohistochemical Analysis of Neuroendocrine Differentiation in Prostate CancerPathobiology, 2009
- Long‐Term assessment of prostate cancer progression free survival: Evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesisThe Prostate, 2008
- REporting recommendations for tumor MARKer prognostic studies (REMARK)Breast Cancer Research and Treatment, 2006
- Tumour markers for managing men who present with metastatic prostate cancer and serum prostate‐specific antigen levels of <10 ng/mLBJU International, 2005
- Neuroendocrine Differentiation in Hormone Refractory Prostate Cancer Following Androgen Deprivation TherapyEuropean Urology, 2004
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1‐T3/M0 prostatic adenocarcinomaBritish Journal of Urology, 1995